Top

Published in:

Open Access 01-10-2013 | Editorial

Progress in novel cognitive enhancers for cognitive aging and Alzheimer’s disease

Authors: Diana W Shineman, Aaron J Carman, Penny A Dacks, Rachel F Lane, Howard M Fillit

Published in: Alzheimer's Research & Therapy | Issue 5/2013

Abstract

Increased knowledge of the biology of synaptic function has led to the development of novel cognitive-enhancing therapeutic strategies with the potential for increased efficacy and safety. This editorial highlights a diverse array of approaches currently being explored to target cognitive dysfunction due to aging and/or Alzheimer’s disease.

Nehlig A: Is caffeine a cognitive enhancer?. J Alzheimers Dis. 2010, 20 (Suppl 1): S85-S94.PubMed

Nachum-Biala Y, Troen AM: B-vitamins for neuroprotection: narrowing the evidence gap. Biofactors. 2012, 38: 145-150. 10.1002/biof.1006.CrossRefPubMed

Gomez-Pinilla F: Collaborative effects of diet and exercise on cognitive enhancement. Nutr Health. 2011, 20: 165-169. 10.1177/026010601102000401.PubMedCentralCrossRefPubMed

Chiesa A, Calati R, Serretti A: Does mindfulness training improve cognitive abilities? a systematic review of neuropsychological findings. Clin Psychol Rev. 2011, 31: 449-464. 10.1016/j.cpr.2010.11.003.CrossRefPubMed

Noetzel MJ, Gregory KJ, Vinson PN, Manka JT, Stauffer SR, Lindsley CW, Niswender CM, Xiang Z, Conn PJ: A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling. Mol Pharmacol. 2013, 83: 835-847. 10.1124/mol.112.082891.PubMedCentralCrossRefPubMed

Wallace TL, Porter RH: Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease. Biochem Pharmacol. 2011, 82: 891-903. 10.1016/j.bcp.2011.06.034.CrossRefPubMed

Engedal K, Davis B, Richarz U, Han J, Schauble B, Andreasen N: Two galantamine titration regimens in patients switched from donepezil. Acta Neurol Scand. 2012, 126: 37-44. 10.1111/j.1600-0404.2011.01594.x.CrossRefPubMed

Geerts H: Indicators of neuroprotection with galantamine. Brain Res Bull. 2005, 64: 519-524. 10.1016/j.brainresbull.2004.11.002.CrossRefPubMed

Fisher A: Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease. Neurotherapeutics. 2008, 5: 433-442. 10.1016/j.nurt.2008.05.002.CrossRefPubMed

10.

Dawson LA: The central role of 5-HT6 receptors in modulating brain neurochemistry. Int Rev Neurobiol. 2011, 96: 1-26.CrossRefPubMed

11.

Phase II clinical data show statistically significant improvement for Lu AE58054 as addon to donepezil, versus donepezil alone, on cognitive symptoms of Alzheimer's disease.http://investor.lundbeck.com/releasedetail.cfm?releaseid=777646,

12.

Chalermpalanupap T, Kinkead B, Hu WT, Kummer MP, Hammerschmidt T, Heneka MT, Weinshenker D, Levey AI: Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease. Alzheimers Res Ther. 2013, 5: 21-10.1186/alzrt175.PubMedCentralCrossRefPubMed

13.

Kalinin S, Polak PE, Lin SX, Sakharkar AJ, Pandey SC, Feinstein DL: The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease. Neurobiol Aging. 2012, 33: 1651-1663. 10.1016/j.neurobiolaging.2011.04.012.PubMedCentralCrossRefPubMed

14.

Samson RD, Barnes CA: Impact of aging brain circuits on cognition. Eur J Neurosci. 2013, 37: 1903-1915. 10.1111/ejn.12183.PubMedCentralCrossRefPubMed

15.

Arnsten AF, Jin LE: Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. Yale J Biol Med. 2012, 85: 45-58.PubMedCentralPubMed

Title: Progress in novel cognitive enhancers for cognitive aging and Alzheimer’s disease
Authors: Diana W Shineman
Aaron J Carman
Penny A Dacks
Rachel F Lane
Howard M Fillit
Publication date: 01-10-2013
Publisher: BioMed Central
Published in: Alzheimer's Research & Therapy / Issue 5/2013
Electronic ISSN: 1758-9193
DOI: https://doi.org/10.1186/alzrt209

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Progress in novel cognitive enhancers for cognitive aging and Alzheimer’s disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2013

Progression of mild Alzheimer’s disease: knowledge and prediction models required for future treatment strategies

Dominantly Inherited Alzheimer Network: facilitating research and clinical trials

Diets involved in PPAR and PI3K/AKT/PTEN pathway may contribute toneuroprotection in a traumatic brain injury

Apolipoprotein E as a β-amyloid-independent factor in Alzheimer’s disease

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples

Neuroprotective effects of donepezil against cholinergic depletion